Prognostic and diagnostic potential of local and circulating levels of pentraxin 3 in lung cancer patients

Maurizio Infante, Paola Allavena, Cecilia Garlanda, Manuela Nebuloni, Emanuela Morenghi, Daoud Rahal, Massimo Roncalli, Silvio Cavuto, Samantha Angela Pesce, Marta Noemi Monari, Serenella Valaperta, Alessandro Montanelli, Daniel Solomon, Edoardo Bottoni, Valentina Errico, E. Voulaz, Manuela Bossi, Fausto Giuseppe Chiesa, Eliseo Passera, Alberto MantovaniMarco Alloisio

Research output: Contribution to journalArticle

Abstract

There is a well-established link between inflammation and cancer of various organs, but little data are available on inflammation-associated markers of diagnostic and prognostic clinical utility in pulmonary malignancy. Blood samples were prospectively collected from 75 resectable lung cancer patients before surgery and in a cohort of 1,358 high-risk subjects. Serum levels of long pentraxin 3 (PTX3) were determined by high-sensitivity ELISA. PTX3 immunostaining was evaluated by immunohistochemistry in cancer tissue. Serum PTX3 levels in the high-risk population were not predictive of developing subsequent lung cancer or any other malignancy; however, serum PTX3 values in patients with lung cancer were significantly higher compared with cancer-free heavy smokers. With a cutoff of 4.5 ng/ml, specificity was 0.80, sensitivity 0.69, positive predictive value 0.15 and negative predictive value 0.98. The receiver operating curve (ROC) for serum PTX3 had an area under the curve (AUC) of 83.52%. Preoperative serum PTX3 levels in lung cancer patients did not correlate with patient outcome, but high interstitial expression of PTX3 in resected tumor specimens was a significant independent prognostic factor associated with shorter survival (p <0.001). These results support the potential of serum PTX3 as a lung cancer biomarker in high-risk subjects. Furthermore, PTX3 immunohistochemistry findings support the role of local inflammatory mechanisms in determining clinical outcome and suggest that local expression of PTX3 may be of prognostic utility in lung cancer patients. What's new? To examine the relationship between cancer and inflammation, the authors measured serum levels of pentraxin 3, a "cousin" of C-reactive protein, in patients with non-small cell lung cancer. Levels were significantly higher in patients as compared to high-risk cancer-free controls, supporting a role for pentraxin 3 as biomarker in lung cancer. Although serum levels did not correlate with clinical outcome, immunostaining of the inflammatory mediator in lung tissue was associated with shorter patient survival, underscoring the pathogenetic relevance of local inflammation in such disease.

Original languageEnglish
Pages (from-to)983-991
Number of pages9
JournalInternational Journal of Cancer
Volume138
Issue number4
DOIs
Publication statusPublished - Feb 15 2016

Fingerprint

Lung Neoplasms
Serum
Neoplasms
Inflammation
PTX3 protein
Immunohistochemistry
Lung
Survival
Tumor Biomarkers
Non-Small Cell Lung Carcinoma
C-Reactive Protein
Area Under Curve
Biomarkers
Enzyme-Linked Immunosorbent Assay

Keywords

  • biomarker
  • inflammation
  • NSCLC
  • PTX3

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Prognostic and diagnostic potential of local and circulating levels of pentraxin 3 in lung cancer patients. / Infante, Maurizio; Allavena, Paola; Garlanda, Cecilia; Nebuloni, Manuela; Morenghi, Emanuela; Rahal, Daoud; Roncalli, Massimo; Cavuto, Silvio; Pesce, Samantha Angela; Monari, Marta Noemi; Valaperta, Serenella; Montanelli, Alessandro; Solomon, Daniel; Bottoni, Edoardo; Errico, Valentina; Voulaz, E.; Bossi, Manuela; Chiesa, Fausto Giuseppe; Passera, Eliseo; Mantovani, Alberto; Alloisio, Marco.

In: International Journal of Cancer, Vol. 138, No. 4, 15.02.2016, p. 983-991.

Research output: Contribution to journalArticle

Infante, Maurizio ; Allavena, Paola ; Garlanda, Cecilia ; Nebuloni, Manuela ; Morenghi, Emanuela ; Rahal, Daoud ; Roncalli, Massimo ; Cavuto, Silvio ; Pesce, Samantha Angela ; Monari, Marta Noemi ; Valaperta, Serenella ; Montanelli, Alessandro ; Solomon, Daniel ; Bottoni, Edoardo ; Errico, Valentina ; Voulaz, E. ; Bossi, Manuela ; Chiesa, Fausto Giuseppe ; Passera, Eliseo ; Mantovani, Alberto ; Alloisio, Marco. / Prognostic and diagnostic potential of local and circulating levels of pentraxin 3 in lung cancer patients. In: International Journal of Cancer. 2016 ; Vol. 138, No. 4. pp. 983-991.
@article{1c8d9676a0684c748d8633a0ac4e5cb9,
title = "Prognostic and diagnostic potential of local and circulating levels of pentraxin 3 in lung cancer patients",
abstract = "There is a well-established link between inflammation and cancer of various organs, but little data are available on inflammation-associated markers of diagnostic and prognostic clinical utility in pulmonary malignancy. Blood samples were prospectively collected from 75 resectable lung cancer patients before surgery and in a cohort of 1,358 high-risk subjects. Serum levels of long pentraxin 3 (PTX3) were determined by high-sensitivity ELISA. PTX3 immunostaining was evaluated by immunohistochemistry in cancer tissue. Serum PTX3 levels in the high-risk population were not predictive of developing subsequent lung cancer or any other malignancy; however, serum PTX3 values in patients with lung cancer were significantly higher compared with cancer-free heavy smokers. With a cutoff of 4.5 ng/ml, specificity was 0.80, sensitivity 0.69, positive predictive value 0.15 and negative predictive value 0.98. The receiver operating curve (ROC) for serum PTX3 had an area under the curve (AUC) of 83.52{\%}. Preoperative serum PTX3 levels in lung cancer patients did not correlate with patient outcome, but high interstitial expression of PTX3 in resected tumor specimens was a significant independent prognostic factor associated with shorter survival (p <0.001). These results support the potential of serum PTX3 as a lung cancer biomarker in high-risk subjects. Furthermore, PTX3 immunohistochemistry findings support the role of local inflammatory mechanisms in determining clinical outcome and suggest that local expression of PTX3 may be of prognostic utility in lung cancer patients. What's new? To examine the relationship between cancer and inflammation, the authors measured serum levels of pentraxin 3, a {"}cousin{"} of C-reactive protein, in patients with non-small cell lung cancer. Levels were significantly higher in patients as compared to high-risk cancer-free controls, supporting a role for pentraxin 3 as biomarker in lung cancer. Although serum levels did not correlate with clinical outcome, immunostaining of the inflammatory mediator in lung tissue was associated with shorter patient survival, underscoring the pathogenetic relevance of local inflammation in such disease.",
keywords = "biomarker, inflammation, NSCLC, PTX3",
author = "Maurizio Infante and Paola Allavena and Cecilia Garlanda and Manuela Nebuloni and Emanuela Morenghi and Daoud Rahal and Massimo Roncalli and Silvio Cavuto and Pesce, {Samantha Angela} and Monari, {Marta Noemi} and Serenella Valaperta and Alessandro Montanelli and Daniel Solomon and Edoardo Bottoni and Valentina Errico and E. Voulaz and Manuela Bossi and Chiesa, {Fausto Giuseppe} and Eliseo Passera and Alberto Mantovani and Marco Alloisio",
year = "2016",
month = "2",
day = "15",
doi = "10.1002/ijc.29822",
language = "English",
volume = "138",
pages = "983--991",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Prognostic and diagnostic potential of local and circulating levels of pentraxin 3 in lung cancer patients

AU - Infante, Maurizio

AU - Allavena, Paola

AU - Garlanda, Cecilia

AU - Nebuloni, Manuela

AU - Morenghi, Emanuela

AU - Rahal, Daoud

AU - Roncalli, Massimo

AU - Cavuto, Silvio

AU - Pesce, Samantha Angela

AU - Monari, Marta Noemi

AU - Valaperta, Serenella

AU - Montanelli, Alessandro

AU - Solomon, Daniel

AU - Bottoni, Edoardo

AU - Errico, Valentina

AU - Voulaz, E.

AU - Bossi, Manuela

AU - Chiesa, Fausto Giuseppe

AU - Passera, Eliseo

AU - Mantovani, Alberto

AU - Alloisio, Marco

PY - 2016/2/15

Y1 - 2016/2/15

N2 - There is a well-established link between inflammation and cancer of various organs, but little data are available on inflammation-associated markers of diagnostic and prognostic clinical utility in pulmonary malignancy. Blood samples were prospectively collected from 75 resectable lung cancer patients before surgery and in a cohort of 1,358 high-risk subjects. Serum levels of long pentraxin 3 (PTX3) were determined by high-sensitivity ELISA. PTX3 immunostaining was evaluated by immunohistochemistry in cancer tissue. Serum PTX3 levels in the high-risk population were not predictive of developing subsequent lung cancer or any other malignancy; however, serum PTX3 values in patients with lung cancer were significantly higher compared with cancer-free heavy smokers. With a cutoff of 4.5 ng/ml, specificity was 0.80, sensitivity 0.69, positive predictive value 0.15 and negative predictive value 0.98. The receiver operating curve (ROC) for serum PTX3 had an area under the curve (AUC) of 83.52%. Preoperative serum PTX3 levels in lung cancer patients did not correlate with patient outcome, but high interstitial expression of PTX3 in resected tumor specimens was a significant independent prognostic factor associated with shorter survival (p <0.001). These results support the potential of serum PTX3 as a lung cancer biomarker in high-risk subjects. Furthermore, PTX3 immunohistochemistry findings support the role of local inflammatory mechanisms in determining clinical outcome and suggest that local expression of PTX3 may be of prognostic utility in lung cancer patients. What's new? To examine the relationship between cancer and inflammation, the authors measured serum levels of pentraxin 3, a "cousin" of C-reactive protein, in patients with non-small cell lung cancer. Levels were significantly higher in patients as compared to high-risk cancer-free controls, supporting a role for pentraxin 3 as biomarker in lung cancer. Although serum levels did not correlate with clinical outcome, immunostaining of the inflammatory mediator in lung tissue was associated with shorter patient survival, underscoring the pathogenetic relevance of local inflammation in such disease.

AB - There is a well-established link between inflammation and cancer of various organs, but little data are available on inflammation-associated markers of diagnostic and prognostic clinical utility in pulmonary malignancy. Blood samples were prospectively collected from 75 resectable lung cancer patients before surgery and in a cohort of 1,358 high-risk subjects. Serum levels of long pentraxin 3 (PTX3) were determined by high-sensitivity ELISA. PTX3 immunostaining was evaluated by immunohistochemistry in cancer tissue. Serum PTX3 levels in the high-risk population were not predictive of developing subsequent lung cancer or any other malignancy; however, serum PTX3 values in patients with lung cancer were significantly higher compared with cancer-free heavy smokers. With a cutoff of 4.5 ng/ml, specificity was 0.80, sensitivity 0.69, positive predictive value 0.15 and negative predictive value 0.98. The receiver operating curve (ROC) for serum PTX3 had an area under the curve (AUC) of 83.52%. Preoperative serum PTX3 levels in lung cancer patients did not correlate with patient outcome, but high interstitial expression of PTX3 in resected tumor specimens was a significant independent prognostic factor associated with shorter survival (p <0.001). These results support the potential of serum PTX3 as a lung cancer biomarker in high-risk subjects. Furthermore, PTX3 immunohistochemistry findings support the role of local inflammatory mechanisms in determining clinical outcome and suggest that local expression of PTX3 may be of prognostic utility in lung cancer patients. What's new? To examine the relationship between cancer and inflammation, the authors measured serum levels of pentraxin 3, a "cousin" of C-reactive protein, in patients with non-small cell lung cancer. Levels were significantly higher in patients as compared to high-risk cancer-free controls, supporting a role for pentraxin 3 as biomarker in lung cancer. Although serum levels did not correlate with clinical outcome, immunostaining of the inflammatory mediator in lung tissue was associated with shorter patient survival, underscoring the pathogenetic relevance of local inflammation in such disease.

KW - biomarker

KW - inflammation

KW - NSCLC

KW - PTX3

UR - http://www.scopus.com/inward/record.url?scp=84954360182&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954360182&partnerID=8YFLogxK

U2 - 10.1002/ijc.29822

DO - 10.1002/ijc.29822

M3 - Article

VL - 138

SP - 983

EP - 991

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 4

ER -